Prasugrel during primary percutaneous coronary intervention: evidence from clinical data
Giuseppe Biondi-Zoccai1, Antonio Abbate, Fabrizio D'Ascenzo
1Division of Cardiology, University of Modena and Reggio Emilia, Via Del Pozzo 71, Modena, Italy. gbiondizoccai@gmail.com
Insights
Dual antiplatelet therapy is crucial after percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI). Newer agents like prasugrel offer potent antithrombotic effects but increase bleeding risk, necessitating individualized treatment decisions.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Primary percutaneous coronary intervention (PCI) with stent implantation is standard for ST-elevation myocardial infarction (STEMI).
- Antithrombotic therapy is vital post-PCI to prevent thrombotic events while managing bleeding risk.
- Aspirin and clopidogrel were the standard oral antiplatelet therapy.
Purpose of the Study:
- To evaluate the role of novel antithrombotic agents in STEMI management.
- To compare the efficacy and safety of prasugrel versus traditional therapies.
- To inform individualized antithrombotic treatment strategies.
Main Methods:
- Review of randomized trials evaluating prasugrel in STEMI patients undergoing PCI.
- Analysis of antithrombotic efficacy and bleeding risk associated with prasugrel, clopidogrel, and ticagrelor.
- Assessment of patient-specific factors influencing treatment decisions.
Main Results:
- Prasugrel demonstrates potent antithrombotic effects in STEMI patients.
- Prasugrel is associated with a statistically significant increase in bleeding risk.
- Increased bleeding risk with prasugrel is noted in elderly, low-body-weight, and stroke/TIA patients.
Conclusions:
- Individualized selection of antithrombotic therapy (prasugrel, clopidogrel, ticagrelor) is essential for STEMI patients undergoing PCI.
- Balancing potent antithrombotic benefits against increased bleeding hazards is critical.
- Patient-specific factors must guide the choice of antiplatelet agent to optimize outcomes.
Abstract:
Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care